If Democrats win control of the House of Representatives, is it time for investors to panic? Jim Cramer asked

"RealMoney" radio show listeners Tuesday.

There's been all the usual hand-wringing over the prospects of a Democrat-controlled Congress, he said, thanks to the assumption that Republicans are supposed to be more fiscally prudent.

But when it comes to runaway spending, an unbalanced budget and too much borrowing, "we already have that for heaven's sake," he said.

This government has done nothing good for the dollar, and the stock market is suffering, he said. Cramer also reminded listeners that there is nothing to fear from a two-party government and that the best gains he's seen in stocks happened when Congress was controlled by Republicans, and Democrats were in the White House.

Government gridlock is good for the market because then the politicians stay out of our way, he said.

Techs are getting hit especially hard in this environment, Cramer said, because people worry that more

Federal Reserve

rate hikes will result in less spending on consumer electronics.

This happened in 2000, so it could happen again. However, Cramer said that this doesn't mean that all technology plays are worth dumping.

He said to go after stocks based on product cycles and specific company stories. For example, he said that business at

Motorola

(MOT)

and

Nokia

(NOK) - Get Report

is thriving.

Cramer believes this is because the companies are not just levered to the U.S. economy. A lot of their growth is coming from overseas, he said, adding that expanding your scope overseas will allow people to avoid some of these Fed-related problems.

Sometimes good news happens, and a stock refuses to move higher. Cramer said that this is often because the market has "discounted" the news before it happens.

This is not the discount you get at the supermarket, he said. The term is used when good news is known about well in advance of the event.

For example, the drug Tysabri was withdrawn last year because it was linked to a rare, but fatal, brain disease. This hurt

Biogen Idec

(BIIB) - Get Report

and

Elan

(ELN)

, which make the treatment.

But both companies have long been telling the market that approval for Tysabri was coming, so when it got permission Monday to resume sales, no one was surprised.

The good news was there, but the stocks slid lower.

The time to own these stocks was when people had given up on Tysabri, Cramer said; the time to sell was when everyone realized that the drug would hit the market again.

To see the most recent edition of The RealMoney Radio Recap in its entirety, please click here. This recap is published every day around 3 p.m. ET.

Jim Cramer is a director and co-founder of TheStreet.com. He contributes daily market commentary for TheStreet.com's sites and serves as an adviser to the company's CEO. Outside contributing columnists for TheStreet.com and RealMoney.com, including Cramer, may, from time to time, write about stocks in which they have a position. In such cases, appropriate disclosure is made. To see his personal portfolio and find out what trades Cramer will make before he makes them, sign up for

Action Alerts PLUS. Listen to Cramer's RealMoney Radio show on your computer; just click

here. Watch Cramer on "Mad Money" at 6 p.m. ET weeknights on CNBC. Click

here to order Cramer's latest book, "Real Money: Sane Investing in an Insane World," click

here to get his second book, "You Got Screwed!" and click

here to order Cramer's autobiography, "Confessions of a Street Addict." While he cannot provide personalized investment advice or recommendations, he invites you to send comments on his column by

clicking here.

TheStreet.com has a revenue-sharing relationship with Traders' Library under which it receives a portion of the revenue from Traders' Library purchases by customers directed there from TheStreet.com.